SUMMARY FOR PATIENTS AND FAMILIES

PBTC-049: A Phase I study of Savolitinib in Recurrent, Progressive, or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS tumors harboring MET aberrations

This study is being undertaken by the Pediatric Brain Tumor Consortium (PBTC). The PBTC is a group that is dedicated to improving treatment options for childhood brain tumors. It is made up of 11 academic centers and children's hospitals in the United States.

The following is a brief summary of a clinical trial, a type of therapeutic research study. Clinical trials include only patients who choose, or whose parents permit them, to take part in the research study. Participation is entirely voluntary.

Who might be eligible to participate in PBTC-049?

Patients with confirmed medulloblastoma, high-grade glioma, DIPG brain tumors, and other brain tumor types with a specific genetic marker, which continue to grow or have come back after the prior treatment may be eligible to participate. Patients must be between 5-21 years of age. Patients must have recovered from toxicities of all prior chemotherapy, immunotherapy, radiotherapy or any other treatment modality prior to entering this study. Pregnant women and nursing mothers are excluded from this study.

Why is PBTC-049 being undertaken?

For pediatric patients who have recurrent CNS tumors with a poor prognosis, there is a clear need to develop more effective therapies. PBTC-049 tests a drug called savolitinib to see how well it works in children with these tumors. This drug has not been studied in children. The hope is that this drug may be a more effective treatment for these types of brain tumors in children. Therefore, the primary goals of the study are to:

- Determine which dose of savolitinib is safe for children
- Learn what effects (good or bad) may occur when patients take savolitinib
- Learn how the body processes savolitinib

What is involved in this study?

Treatment will generally be administered on an outpatient basis. Savolitinib dosing will begin at 150 mg/m²/dose. Patients will receive savolitinib once a day orally on a continuous basis. Twenty-eight (28) consecutive days (4 weeks) will constitute one course. Patients may continue to receive savolitinib for 39 courses (approximately 3 years). If the patient misses a dose, the patient should take the dose as soon as possible or within 12 hours after the missed dose. If the patient misses a dose by more than 12 hours, the dose should be withheld and the patient should wait until the scheduled time for the next dose (i.e., patients should not make up the missed dose after 12 hours). The patient should then continue treatment with the original dosing schedule. Prior to and during the study, patients will undergo routine medical tests and procedures.
If you decide to participate in this study, you can continue for as long as 3 years. During that time, you will need to see your study doctor every week for the first course (28 days) and then at least every 4 weeks. If you experience bad side effects, you might have to return more frequently or even be in the hospital.

**What are the risks of participating in PBTC-049?**

There is a risk that you can have side effects from the study drug. Some of the most common side effects that the study doctors know about are: Nausea, vomiting, constipation, diarrhea, tiredness, swelling of arms and/or legs, allergic reactions, liver damage (which may cause yellowing of the eyes and skin), and loss of appetite. There are some dermatologic side effects such as progressive skin rash with blisters or mucosal lesions are reported. There may be some risks that the study doctors do not yet know about.

There may be unknown risks and discomforts involved in participating in this or any clinical trial. In the event of adverse effects, the health care team may modify the treatment and/or incorporate additional medical tests to monitor the adverse effects. Doctors will notify parents and patients immediately of any important information or treatment findings discovered during the study that may affect their willingness to continue to participate.

**What if I have more questions about PBTC-049?**

If you would like more information, please contact the PBTC member institution closest to you. You can also contact the doctor in charge of this study:

**Ralph Salloum, MD**  
Cincinnati Children’s Hospital Medical Center  
3333 Burnett Avenue  
Cincinnati, OH, 45229  
Telephone: 513-803-1126  
Fax: 513-636-5349  
Email: Ralph.salloum@cchmc.org

Other information will be available through the following:  
The National Cancer Institute’s (NCI) Cancer Information Service at 1-800-422-6237 or TTY: 1-800-332-8615 or through the NCI’s websites [www.cancer.gov](http://www.cancer.gov) and [www.cancer.gov/clinicaltrials](http://www.cancer.gov/clinicaltrials).